In short
Clinical trials are investigating Adg126 in people with advanced liver cancers. These studies aim to evaluate how well Adg126 works in immunotherapy-based combinations and how safe the treatment is. The main focus is on treatment response, safety, and lab and heart-related checks in adult patients.
Key points
- Adg126 is being studied in a Phase 1 clinical trial for people with advanced liver cancers. The trial is testing Adg126 in immunotherapy-based treatment combinations, not as a stand-alone study treatment. Researchers are mainly looking at safety and early signs of benefit, especially objective response rate, or ORR. They are also checking side effects, lab tests, vital signs, and ECG results. The trial is authorised and plans to enroll 309 participants.
Trial overview
The available study is Morpheus-Liver, a trial called “A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers.”
This is an interventional study, which means researchers assign the treatment plan to the participants instead of only watching what happens naturally.
The trial is in Phase 1, so it is an early study that mainly looks at safety and early signs of benefit.
Who can participate
The study is for patients with advanced liver cancers.
The source data do not list detailed entry rules such as age limits, prior treatments, or lab requirements, so the main known target group is people with this cancer type.
What is being studied
Adg126 is being studied as part of several immunotherapy-based treatment combinations.
The trial title and brief summary show that the study aims to evaluate the efficacy of these combinations, which means how well they work against the cancer, and their safety, which means how well participants tolerate them.
Other study treatments listed in the trial include RO7790118, RO7791094, Tiragolumab, Avastin, RO7247669, Tecentriq, TPST-1120, and RoActemra, showing that the study is testing multiple treatment groups rather than only one plan.
Main outcomes and measurements
The main cancer outcome is objective response rate, or ORR, measured by the investigator using RECIST 1.1.
ORR tells researchers how many patients have a measurable tumor response, such as shrinkage, on imaging scans.
The study also measures the incidence, nature, and severity of adverse events and laboratory abnormalities.
In addition, researchers track changes from baseline in vital signs, ECG parameters, and targeted clinical laboratory test results.
Status and study size
The trial status is Authorised.
The planned enrollment is 309 participants, which means the study is designed to include 309 people in total.